X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9218) 9218
Book Review (1751) 1751
Publication (910) 910
Conference Proceeding (69) 69
Book Chapter (43) 43
Dissertation (14) 14
Magazine Article (11) 11
Web Resource (9) 9
Reference (2) 2
Book / eBook (1) 1
Data Set (1) 1
Government Document (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cetuximab (7507) 7507
index medicus (6637) 6637
humans (6565) 6565
oncology (4927) 4927
female (2914) 2914
male (2751) 2751
chemotherapy (2664) 2664
cancer (2517) 2517
middle aged (2371) 2371
colorectal cancer (2212) 2212
antibodies, monoclonal, humanized (2209) 2209
aged (2170) 2170
colorectal neoplasms - drug therapy (1859) 1859
antineoplastic agents - therapeutic use (1787) 1787
adult (1689) 1689
antineoplastic combined chemotherapy protocols - therapeutic use (1662) 1662
antibodies, monoclonal - therapeutic use (1618) 1618
growth-factor receptor (1593) 1593
receptor, epidermal growth factor - antagonists & inhibitors (1504) 1504
mutation (1342) 1342
egfr (1340) 1340
colorectal neoplasms - pathology (1338) 1338
treatment outcome (1324) 1324
bevacizumab (1239) 1239
care and treatment (1207) 1207
colorectal neoplasms - genetics (1165) 1165
metastasis (1158) 1158
animals (1149) 1149
therapy (1088) 1088
1st-line treatment (1014) 1014
panitumumab (1003) 1003
aged, 80 and over (999) 999
cell line, tumor (993) 993
epidermal growth factor (967) 967
antibodies, monoclonal - administration & dosage (950) 950
tumors (923) 923
prognosis (922) 922
fluorouracil (889) 889
metastatic colorectal-cancer (882) 882
receptor, epidermal growth factor - metabolism (875) 875
research (854) 854
survival (853) 853
radiotherapy (843) 843
kras (814) 814
oxaliplatin (814) 814
disease-free survival (809) 809
squamous-cell carcinoma (807) 807
expression (802) 802
ras proteins - genetics (791) 791
analysis (776) 776
monoclonal antibodies (771) 771
hematology, oncology and palliative medicine (730) 730
antineoplastic agents - pharmacology (723) 723
carcinoma, squamous cell - drug therapy (717) 717
mice (714) 714
neoplasm metastasis (709) 709
proto-oncogene proteins p21 (708) 708
head and neck neoplasms - drug therapy (704) 704
proto-oncogene proteins - genetics (701) 701
camptothecin - analogs & derivatives (676) 676
antineoplastic agents (666) 666
antibodies, monoclonal - adverse effects (661) 661
medicine & public health (655) 655
pharmacology & pharmacy (655) 655
squamous cell carcinoma (648) 648
drug therapy (645) 645
epidermal growth factor receptor (645) 645
head and neck cancer (633) 633
antineoplastic agents - adverse effects (629) 629
irinotecan (626) 626
antimitotic agents (623) 623
trial (621) 621
carcinoma (613) 613
cisplatin (607) 607
plus cetuximab (598) 598
leucovorin (596) 596
colorectal-cancer (592) 592
health aspects (581) 581
surgery (581) 581
retrospective studies (577) 577
neoplasm staging (576) 576
fluorouracil - administration & dosage (573) 573
antibodies, monoclonal - pharmacology (572) 572
receptor, epidermal growth factor - genetics (566) 566
cell lung-cancer (565) 565
phase-iii trial (559) 559
genetic aspects (557) 557
cancer therapies (549) 549
neoplasms (536) 536
gefitinib (525) 525
antineoplastic combined chemotherapy protocols - adverse effects (513) 513
open-label (505) 505
digestive system diseases (501) 501
phase-ii (500) 500
combination (498) 498
cetuximab plus irinotecan (493) 493
patients (492) 492
camptothecin - administration & dosage (490) 490
erlotinib (489) 489
lung neoplasms - drug therapy (486) 486
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8611) 8611
French (204) 204
German (155) 155
Japanese (136) 136
Spanish (64) 64
Chinese (50) 50
Czech (29) 29
Korean (18) 18
Hungarian (14) 14
Italian (9) 9
Turkish (7) 7
Dutch (6) 6
Polish (6) 6
Russian (6) 6
Norwegian (3) 3
Finnish (2) 2
Hebrew (2) 2
Portuguese (2) 2
Catalan (1) 1
Danish (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 12/2018, Volume 16, Issue 12, pp. 1547 - 1548
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2015, Volume 33, Issue 21, pp. 2408 - U114
Journal Article
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 8, pp. 1710 - 1714
Journal Article
10/2011
Molecular targeted agents have lower hematological toxicity. However, specific side-effects such as allergic rashes, skin reactions and high cost limit their... 
thrombosis | chemoradiotherapy | Cetuximab
Web Resource
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 1, pp. 110 - 117
Purpose To assess the rate of serious (>Grade 2, CTCAE 3.0) dermatitis in our head-and-neck cancer (HNC) patients undergoing simultaneous integrated boost... 
Radiology | Hematology, Oncology and Palliative Medicine | Cetuximab and IMRT | Cetuximab-related dermatitis | Cetuximab in irradiated head neck cancer | Cetuximab and bolus material | RADIOTHERAPY PLUS CETUXIMAB | RASH | ONCOLOGY-GROUP | PHASE-III | SECONDARY | RANDOMIZED-TRIAL | COMBINATION | RADIATION-THERAPY | CISPLATIN | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Prospective Studies | Drug Eruptions - pathology | Humans | Middle Aged | Radiodermatitis - chemically induced | Antibodies, Monoclonal - adverse effects | Male | Antineoplastic Agents - administration & dosage | Case-Control Studies | Radiotherapy, Intensity-Modulated - adverse effects | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Cetuximab | Radiodermatitis - pathology | Drug Eruptions - etiology | Radiotherapy, Intensity-Modulated - methods | Radiation Dosage | Tumor Burden | Combined Modality Therapy - adverse effects | Head and Neck Neoplasms - pathology | Head and Neck Neoplasms - radiotherapy | Antibodies, Monoclonal - administration & dosage | Aged | Combined Modality Therapy - methods | Index Medicus | HEAD | NEOPLASMS | DERMATITIS | RADIATION DOSES | SKIN DISEASES | MEDICINE | NUCLEAR MEDICINE | ORGANS | NECROSIS | DISEASES | THERAPY | DOSES | RADIOLOGY AND NUCLEAR MEDICINE | NECK | RADIOTHERAPY | SKIN | BODY | PATHOLOGICAL CHANGES | RADIOLOGY
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 09/2008, Volume 49, Issue 9, pp. 1472 - 1479
Journal Article
05/2010
Aim: The aim of the present study was to compare the efficacy and safety of weekly versus an every 2-week administration of cetuximab in association with... 
weekly cetuximab | Cetuximab given every 2 weeks | metastatic colorectal cancer
Web Resource
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3658 - 3666
Journal Article
Nature, ISSN 0028-0836, 10/2015, Volume 526, Issue 7572, pp. 263 - 267
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly... 
PANITUMUMAB | THERAPY | MULTIDISCIPLINARY SCIENCES | SEQUENCE | ACQUIRED-RESISTANCE | SOMATIC MUTATION | IDENTIFICATION | GENE COPY NUMBER | ACTIVATING MUTATIONS | BREAST | INSIGHTS | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Genomics | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Molecular Targeted Therapy | Receptor, Fibroblast Growth Factor, Type 1 - genetics | MAP Kinase Kinase 1 - genetics | Colorectal Neoplasms - drug therapy | Female | Antineoplastic Agents - pharmacology | Insulin Receptor Substrate Proteins - genetics | Colorectal Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Cetuximab - pharmacology | DNA Copy Number Variations - genetics | Mutation - genetics | Genome, Human - genetics | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Exome - genetics | Animals | Receptor, Platelet-Derived Growth Factor alpha - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Gene mutations | Colorectal cancer | Drug metabolism | Genetic aspects | Identification and classification | Health aspects | Proteins | Epidermal growth factor | Genes | Clinical trials | Mutation | Kinases | Cancer therapies | Tumors | Index Medicus
Journal Article
Journal Article
The Laryngoscope, ISSN 0023-852X, 07/2017, Volume 127, Issue 7, pp. 1583 - 1588
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2017, Volume 258, pp. 196 - 207
Journal Article
Journal of Oncology Pharmacy Practice, ISSN 1078-1552, 12/2018, Volume 24, Issue 8, pp. 632 - 633
Cetuximab is a monoclonal antibody against epidermal growth factor receptor and is used in the treatment of head and neck cancer, non-small cell lung cancer,... 
chemical meningitis | drug-induced meningitis | adverse events cetuximab | Cetuximab-induced aseptic meningitis | side effects cetuximab | cetuximab | metastatic colon cancer |